The One Man Shoot is thrilled to welcome Dr. Oliver Sartor back to Louisiana! He is a globally recognized expert in prostate cancer. He is now the Director of the Transformational Prostate Cancer Research Center at East Jefferson General Hospital Cancer Center. With over thirty years of dedicated experience in improving care for men, particularly those facing advanced, treatment-resistant disease, Dr. Sartor brings an unparalleled level of expertise and innovation back to the region.

In his new role, Dr. Sartor will lead the newly established Transformational Prostate Cancer Research Center. He will be responsible for both providing direct patient care and continuing his groundbreaking research, with a primary focus on improving both the longevity and quality of life for men battling prostate cancer. His arrival significantly strengthens the commitment to providing cutting-edge, comprehensive cancer care to the Greater New Orleans community, Baton Rouge and well beyond.

​

His reputation as a leading expert in prostate cancer, coupled with his vast experience and dedication to pioneering research, will undoubtedly elevate the level of care provided to prostate cancer patients. Dr. Sartor’s leadership of the new Transformational Prostate Cancer Research Center significantly increases local innovation and excellence in cancer treatment.

​

Dr. Sartor earned his MD with honors from Tulane University School of Medicine and completed his training at the University of Pennsylvania, Tulane and the National Cancer Institute (NCI), where he began pioneering work on novel therapeutics for prostate cancer. Throughout his distinguished career, he has held leadership roles at prestigious institutions, including LSU Health Sciences Center, Dana-Farber Cancer Institute/Harvard Medical School, Tulane University and, most recently, Mayo Clinic, where he served as Professor of Medical Oncology, Director of Radiopharmaceutical Trials and Chief of the Genitourinary Cancer Disease Group.

​

Dr. Sartor collaborates widely with leading researchers both in the USA and at several international sites including Australia, Norway, France, Germany, and the UK. 

 

“This is an exciting new chapter, both personally and professionally,” said Dr. Sartor. “By combining EJGH’s commitment to excellence with our practice-changing research, we have an incredible opportunity to change the trajectory of prostate cancer care — for prostate cancer patients everywhere.”

 

Dr. Sartor’s impressive contributions to the field of prostate cancer research include authoring over 500 peer-reviewed publications and playing key roles in numerous international clinical trials. His work has directly led to multiple FDA-approved treatments for prostate cancer, underscoring his profound impact on the lives of countless patients.